Side by side: size, value over time, results, valuation, margins, growth, debt and shareholder returns, and any of thirty figures charted over the years (up to 6).
Open these as a peer group: up to 12 companies with suggested peers, each company's rank in the group and percentile in its sector and country, saved for you or your team.
US$ billions, as reported in each year's annual results.
Revenue of the fiscal year. US dollars at each year's exchange rate.
| Measure | Hyperfine, Inc.✕ HYPR · #19,654 in the world | Medicalgorithmics S.A.✕ MDG.WA |
|---|---|---|
| Profile | ||
| Country | 🇺🇸 USA | 🇵🇱 Poland |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
| Founded | — | — |
| Size | ||
| Market cap | ||
The largest companies, each against its nearest peers in value from the same industry.
| Fiscal year | Hyperfine, Inc. | Medicalgorithmics S.A. |
|---|---|---|
| 2025 | $14 MSEC | — |
| 2024 | $13 MSEC | — |
| 2023 | $11 MSEC | — |
| 2022 | $7 MSEC | — |
| 2021 | $2 MSEC | — |
| 2020 | $0 MSEC | — |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports; Ed. = the company's report (editors); WD = Wikidata, citing the annual report; Cap = value.today market caps. Hover a figure for its period.
| $78 M |
| $75 M* |
| Revenue | $14 M | — |
|---|
| Net income | $-36 M | — |
|---|
| Employees | 102 | — |
|---|
| Valuation | ||
|---|---|---|
| Price to sales | 4.1× | — |
| Price to book | 1.9× | — |
| Free cash flow yield | -37.6% | — |
| Profitability | ||
|---|---|---|
| Gross margin | 49.8% | — |
| Operating margin | -273.4% | — |
| Net margin | -262.3% | — |
| Return on equity | -79.0% | — |
| Growth | ||
|---|---|---|
| Revenue growth | 5.2% | — |
| Revenue growth, 3 years a year | 25.8% | — |
| Financial strength | ||
|---|---|---|
| Debt to equity | 0.0× | — |
| Cash | ||
|---|---|---|
| Free cash flow margin | -214.8% | — |
| Altman Z-score zone | distress | — |
|---|
| Data as of | Market cap Oct 2026; ratios FY2025 | Market cap Jan 2024 |
|---|
Market caps from exchange data or SEC filings on the date shown (* last known value, no current one); revenue and net income from the latest annual results; ratios worked out from each company's own statements for the fiscal year shown. ▲ marks the best of these companies where higher or lower is better; size and valuation multiples are marked for no one. Definitions: methodology.